AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca has recently updated its clinical study titled A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis. The study aims to assess the safety and effectiveness of AZD4831 in treating NASH, a liver disease characterized by fat accumulation and fibrosis.
The intervention being tested is AZD4831, a drug designed to treat NASH by potentially reducing liver inflammation and fibrosis. The study involves a comparison between AZD4831 and a placebo.
This interventional study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment-focused.
The study began on October 26, 2022, with primary completion expected by March 24, 2025, and the last update submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The completion of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, as successful results may enhance the company’s position in the NASH treatment market. Competitors in the pharmaceutical industry are also eyeing advancements in NASH therapies, making this an area of keen interest.
The study is ongoing, with further details available on the ClinicalTrials portal.